Overview

Full Product Details

Author:   Allen R. Nissenson (Emeritus Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Los Angeles, CA) ,  Richard N. Fine (Professor of Pediatrics, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY) ,  Rajnish Mehrotra, MD, MS (David S. and Nayda Utterberg Endowed Professor, Professor of Medicine, Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA) ,  Joshua Zaritsky, MD, PhD (Chief Pediatric Nephrology, St. Christopher's Hospital for Children, Professor of Pediatrics, Drexel University College of Medicine, Philadelphia, PA)
Publisher:   Elsevier - Health Sciences Division
Imprint:   Elsevier - Health Sciences Division
Edition:   6th edition
Weight:   1.630kg
ISBN:  

9780323791359

ISBN 10:   0323791352
Pages:   944
Publication Date:   11 October 2022
Audience:   Professional and scholarly ,  Professional & Vocational
Replaced By:   9780323445504
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

PART I: Dialysis Therapy for Adults Section 1: Overview of ESKD 1 Demographics of the End-Stage Renal Disease Patient 2 Uremic Toxicity 3 Initiation of Dialysis Therapy Section 2: Hemodialysis 4 Urea Kinetic Modeling for Guiding Hemodialysis Therapy in Adults 5 The Dialysis Prescription 6 Selecting a Dialyzer: Technical and Clinical Considerations 7 Water Treatment Equipment for In-Center Hemodialysis 8 Dialysate Composition 9 Safety Monitors in Hemodialysis 10 Methods of Hemodialysis Anticoagulation 11 Common Clinical Problems in Hemodialysis 12 Hemofiltration and Hemodiafiltration 13 Wearable and Implantable Renal Replacement Therapy 14 Home Preparation and Installation for Home Hemodialysis 15 Vascular Access 16 Cannulation of Arteriovenous Vascular Access: Science and Art 17 Central Venous Access for Hemodialysis 18 Noninfectious Complications From Vascular Access 19 Infectious Complications From Vascular Access Section 3: Peritoneal Dialysis 20 Determination of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis Prescriptions 21 Peritoneal Dialysis Cyclers and Other Mechanical Devices 22 Peritoneal Dialysis Solutions 23 Solute Management With Peritoneal Dialysis 24 Volume Management With Peritoneal Dialysis 25 Peritoneal Access Devices, Placement Techniques, and Maintenance 26 Peritoneal Catheter Exit Site and Tunnel Infections 27 Peritonitis in Peritoneal Dialysis 28 Abdominal Hernias With Peritoneal Dialysis 29 Dialysate Leaks with Peritoneal Dialysis 30 Hydrothorax and Peritoneal Dialysis 31 Abdominal Catastrophes, Peritoneal Eosinophilia, and Other Unusual Events in Peritoneal Dialysis 32 Metabolic Complications of Peritoneal Dialysis Section 4: Management of Uremic Complications 33 Acid-Base Homeostasis in Dialysis 34 Nutritional Management of Hemodialysis Patients 35 Intradialytic Parenteral Nutrition and Intraperitoneal Nutrition 36 Nutritional Management in Peritoneal Dialysis 37 Anemia and Its Treatment in Patients With End-Stage Kidney Disease 38 Resistance to Erythropoiesis Stimulating Agent (ESA) Treatment 39 Chronic Kidney Disease-Mineral and Bone Disorder 40 Phosphate Management in Patients with End-Stage Kidney Disease 41 Use of Vitamin D Sterols and Calcimimetics in Patients With End-Stage Renal Disease 42 Parathyroidectomy 43 Acquired Cystic Kidney Disease Section 5: Management of Co-Existing Illnesses and Special Populations 44 The Challenges of Blood Pressure Control in Hemodialysis Patients 45 Arrhythmias in Hemodialysis Patients 46 Management of Ischemic Heart Disease, Heart Failure, and Pericarditis in Patients Undergoing Long-Term Dialysis 47 Avoidance and Treatment of Cardiovascular Disease in Dialysis 48 Management of Dyslipidemia in Long-Term Dialysis Patients 49 End-Stage Kidney Failure in the Diabetic Patient 50 Care of Elderly Dialysis and End-Stage Kidney Disease Patients 51 Liver Disease and Gastrointestinal Disorders in Dialysis Patients 52 Abnormalities of Thyroid Function in Chronic Dialysis Patients 53 Care of the Human Immunodeficiency Virus-Infected End-Stage Kidney Disease Patient 54 COVID-19 and Dialysis Patients 55 Psychosocial Issues in Patients Treated With Dialysis 56 Evaluation and Treatment of Sexual Dysfunction 57 Pregnancy in Dialysis Patients 58 Principles of Drug Usage in Dialysis Patients 59 Medication Management 60 Physical Activity, Function, and Exercise-Based Rehabilitation for People on Dialysis 61 Physical, Psychosocial, and Vocational Rehabilitation of Patients Undergoing Long-Term Dialysis 62 Preventive Care in End-Stage Renal Disease Section 6: Systems Management for the Care of Dialysis Patients 63 Ethical Considerations in the Care of Dialysis Patients: The New Paradigm 64 Improving Outcomes for End-Stage Renal Disease Patients: Shifting the Quality Paradigm 65 Quality, Safety, Accountability, and Medical Director Responsibilities 66 Application of Telemedicine to Kidney Failure Patients Section 7: Acute Kidney Injury and Poisonings 67 Continuous Renal Replacement Therapies for Acute Kidney Injury 68 Anticoagulation for Continuous Renal Replacement Therapy 69 Treatment of Poisoning with Extracorporeal Methods PART II: Dialysis Therapy for Children 70 Vascular Access and Peritoneal Dialysis Catheter Placement in Children 71 Infant Hemodialysis 72 Urea Kinetic Modeling for Hemodialysis Prescription in Children 73 Alternate Hemodialysis Prescriptions in Children 74 Anticoagulation in Children Undergoing Hemodialysis, Continuous Renal Replacement Therapy, or Apheresis Therapy 75 Prescribing Peritoneal Dialysis in Children 76 Nutritional Management of Children Undergoing Peritoneal Dialysis 77 Peritoneal Dialysis in Neonates and Infants 78 Dialysis for Inborn Errors of Metabolism 79 Neurocognitive Function in Pediatric Dialysis 80 Growth in Children With End-Stage Kidney Disease 81 Adequacy of Peritoneal Dialysis/Assessing Peritoneal Function in Pediatric Patients 82 Continuous Renal Replacement Therapy in Pediatric Patients 83 Prevention and Treatment of Bone Disease in Pediatric Dialysis Patients 84 Management of Anemia in Children Undergoing Dialysis 85 Prevention and Treatment of Cardiovascular Complications in Children Undergoing Dialysis 86 Infectious Complications in Children Undergoing Dialysis 87 Caring for the Teenager in an Adult Unit Index

Reviews

"""This book provides an extensive overview of the routine care of dialysis patients, including different types of dialysis as well as how to deal with complications that can arise for dialysis patients."" ©Doody's Review Service, 2023, Tyler C Sims, MD (University of Kentucky College of Medicine) Doody's Score: 5 Stars!"

Author Information

Dr. Richard E. Fine received his Bachelor's and PhD degrees in Biochemistry from University of California at Berkeley and Brandeis University respectively. He then was a postdoctoral fellow in the laboratory of Francis Crick and Sydney Brenner at the Laboratory of Molecular Biology in Cambridge, U.K. During this period he and his colleague, Dennis Bray provided the first evidence for actin in growing neurons. Dr. Fine became an Assistant Professor of Physiology and Biochemistry at Boston University School of Medicine and demonstrated the existence of actin regulatory molecules, tropomyosin and troponin C in growing neurons, and he subsequently became interested in the role of clathrin coated vesicles in endocytic and exocytic processes in neurons and in other tissues. He also isolated and characterized vasopressin receptors, demonstrated for the first time that a large molecular, transferrin, can cross the blood brain barrier. Our lab in collaboration with Dr. Ken Kosik were the first to show that an antisense oligonucleotide can be used in vivo to block the synthesis of a single protein. Using the rabbit retina we were able to show that an antisense nucleotide against the kinesin mRNA can block the critical role of kinesin in the transport of synaptic vesicles, neuropeptide containing vesicles and vesicles destined for the plasma membrane. In recent years Dr. Fine's laboratory has focused on the role of the amyloid beta peptide in Alzheimer's disease especially in brain capillary endothelium. Also he has recently focused on the role of a mutant protein VPS35, a component of the retromer in Parkinson's and Alzheimer's diseases. During his career he has received over $25,000,000 in grant funding, have served on both NIH and VA review panels and authored or co-authored over 100 research papers.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions